SIGA Awarded a $7.7M Grant for the Development of Antiviral Drugs for Arenaviruses

SIGA Technologies, Inc. SIGA announced today that it has been awarded a $7.7 million grant from the National Institutes of Health to develop an antiviral drug for treating and preventing Lassa fever and other hemorrhagic fevers of Arenavirus origin.